With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.
787618-22-8, General procedure: Representative procedure for the preparation of rPdtoptionally substituted (Ri?), allyl)(liqand)(X) complexes: A dry Schlenk tube is charged with the ligand (4.74 mmol) and [(optionally substituted (Ri2)m- allyl)PdCI]2 (2.36 mmol). The tube is evacuated and backfilled with nitrogen a total of three times. 10 mL of anhydrous solvent (such as THF or toluene) is added and the mixture is stirred at room temperature for a period of time (e.g . 20 minutes). Pentane (5 mL) or hexanes is added to fully precipitate the product. The product is collected by vacuum filtration, washed (3 x 10 mL of pentane, or hexanes) and dried under vacuum
The synthetic route of 787618-22-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; JOHNSON MATTHEY PUBLIC LIMITED COMPANY; COLACOT, Thomas; CHOW, Ruishan; JON DEANGELIS, Andrew; WO2015/189554; (2015); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate